Back to List View Graph View

B-cell Maturation Antigen

B-cell maturation antigen (BCMA) is a protein that serves as a therapeutic target on malignant plasma cells, particularly in multiple myeloma.

1 paper landed today · 16 Nov 2026
  • Successful treatment of systemic light chain amyloidosis with a novel high-avidity BCMA CAR. PMID 43035762

Where the papers sit

13 papers from the last 6 months study B-cell Maturation Antigen directly

  • BCMA Therapies in Myeloma

    BCMA treatment in multiple myeloma is diversifying across CAR T cells, bispecific antibodies, antibody-drug conjugates and CAR-NK cells. Anito-cel and ciltacabtagene autoleucel extend cellular therapy, while teclistamab and linvoseltamab provide antibody-based options. Epitope engagement and BCMA mutations may determine differential activity, and belantamab mafodotin studies link soluble BCMA and serum M-protein to response. CRS, ICANS and frailty remain central safety concerns.

    6 papers · 46.2%

  • CAR-T Cell Therapy

    CAR-T therapy is expanding from refractory myeloma into autoimmune disease, with durable drug-free remission reported in primary immune thrombocytopenia and trials emerging in myasthenia gravis. Triple-knockout allogeneic BCMA CAR-T cells aim to improve availability and persistence. CTLA4 and LAG3 variation may help explain differences in progression-free survival after treatment. The field is moving toward off-the-shelf cells and biomarker-guided immune modulation.

    4 papers · 30.8%

  • BCMA Therapy in Amyloidosis

    BCMA-directed therapy is moving into relapsed or refractory AL amyloidosis, where CAR T cells and bispecific antibodies are producing hematologic responses and organ improvement. Pooled evidence includes minimal residual disease negativity but also Grade 3 cytokine release syndrome. Early high-avidity CAR data support deeper responses, while the French EMMY cohort broadens experience across plasma-cell disease. Prospective studies must clarify durability and safety in amyloidosis.

    3 papers · 23.1%

NEW DIRECTION

BCMA-directed CAR T-cell therapy extends beyond plasma-cell malignancies to durable treatment of autoimmune disease

Refractory primary immune thrombocytopenia was treated with BCMA-directed CAR T cells, producing rapid, sustained platelet recovery and drug-free complete remission lasting up to 15 months 42498681Jul. The set otherwise presents BCMA as a therapeutic target in malignant or dyscratic plasma-cell disorders, so this finding assigns it a role in refractory autoimmune disease and broadens BCMA-directed cellular therapy beyond cancer treatment.

Papers

The 13 papers from the last 6 months that study B-cell Maturation Antigen directly, newest first, by theme and by study type. Study types come from PubMed publication types and MeSH headings.

By theme

BCMA Therapies in Myeloma (6)
  1. Simultaneous Population PKPD Analysis of Belantamab Mafodotin, Soluble BCMA, and Serum M-Protein in Relapsed/Refractory Multiple Myeloma. CPT: pharmacometrics & systems pharmacology · 30 Sept 2026 PMID 42811422
  2. Efficacy and safety of frail patients treated with ciltacabtagene autoleucel in the real world: A Center for International Blood and Marrow Transplant Research analysis. Cancer · 24 Sept 2026 PMID 42779338
  3. Phase 1 Study of Anito-cel, a d-Domain BCMA CAR T Cell for Refractory or Recurrent Myeloma. The New England journal of medicine · 23 Sept 2026 PMID 42777241
  4. Teclistamab-associated adverse events: a disproportionality analysis of the FDA adverse event reporting system. Hematology (Amsterdam, Netherlands) · 15 Sept 2026 PMID 42742109
  5. Anti-BCMA CAR-NK Cells Reveal Enhanced Cytolytic and Secretory Responses Against Myeloma Cells. APMIS : acta pathologica, microbiologica, et immunologica Scandinavica · 2 Sept 2026 PMID 42682210
  6. Distinct epitope engagement confers differential activity of linvoseltamab vs teclistamab across BCMA mutations. Blood advances · 27 Jul 2026 PMID 42509021
CAR-T Cell Therapy (4)
  1. Clinical Impact of CTLA4 and LAG3 Single-Nucleotide Polymorphisms in Multiple Myeloma Patients Treated With BCMA CAR T-Cell Therapy. Hematological oncology · 29 Sept 2026 PMID 42806527
  2. Generalized myasthenia gravis: Clinical trials to watch. Med (New York, N.Y.) · 11 Sept 2026 PMID 42727567
  3. BCMA-directed CAR T-cell therapy induces durable drug-free remission in refractory primary immune thrombocytopenia. Blood · 24 Jul 2026 PMID 42498681
  4. A novel triple-knockout allogeneic BCMA CAR T-cell therapy (CT0590) for multiple myeloma: preclinical and phase 1 study. Blood · 11 Jun 2026 PMID 42275247
BCMA Therapy in Amyloidosis (3)
  1. Successful treatment of systemic light chain amyloidosis with a novel high-avidity BCMA CAR. Journal of hematology & oncology · 15 Nov 2026 PMID 43035762
  2. BCMA Targeted Therapies and Their Impact on Outcomes in Relapsed or Refractory Multiple Myeloma: Results From the French EMMY Cohort. European journal of haematology · 29 Sept 2026 PMID 42810732
  3. Efficacy and safety of BCMA-targeted therapies in relapsed or refractory AL amyloidosis: a descriptive pooled analysis. Blood advances · 21 Jul 2026 PMID 42478693

By study type

Clinical trials (2)
  1. Phase 1 Study of Anito-cel, a d-Domain BCMA CAR T Cell for Refractory or Recurrent Myeloma. The New England journal of medicine · 23 Sept 2026 PMID 42777241
  2. A novel triple-knockout allogeneic BCMA CAR T-cell therapy (CT0590) for multiple myeloma: preclinical and phase 1 study. Blood · 11 Jun 2026 PMID 42275247
Observational studies and case reports (3)
  1. Clinical Impact of CTLA4 and LAG3 Single-Nucleotide Polymorphisms in Multiple Myeloma Patients Treated With BCMA CAR T-Cell Therapy. Hematological oncology · 29 Sept 2026 PMID 42806527
  2. Efficacy and safety of frail patients treated with ciltacabtagene autoleucel in the real world: A Center for International Blood and Marrow Transplant Research analysis. Cancer · 24 Sept 2026 PMID 42779338
  3. Teclistamab-associated adverse events: a disproportionality analysis of the FDA adverse event reporting system. Hematology (Amsterdam, Netherlands) · 15 Sept 2026 PMID 42742109
Human data, design not indexed (5)
  1. Successful treatment of systemic light chain amyloidosis with a novel high-avidity BCMA CAR. Journal of hematology & oncology · 15 Nov 2026 PMID 43035762
  2. Simultaneous Population PKPD Analysis of Belantamab Mafodotin, Soluble BCMA, and Serum M-Protein in Relapsed/Refractory Multiple Myeloma. CPT: pharmacometrics & systems pharmacology · 30 Sept 2026 PMID 42811422
  3. Generalized myasthenia gravis: Clinical trials to watch. Med (New York, N.Y.) · 11 Sept 2026 PMID 42727567
  4. BCMA-directed CAR T-cell therapy induces durable drug-free remission in refractory primary immune thrombocytopenia. Blood · 24 Jul 2026 PMID 42498681
  5. Efficacy and safety of BCMA-targeted therapies in relapsed or refractory AL amyloidosis: a descriptive pooled analysis. Blood advances · 21 Jul 2026 PMID 42478693
Preclinical: animal, cell and lab studies (2)
  1. Anti-BCMA CAR-NK Cells Reveal Enhanced Cytolytic and Secretory Responses Against Myeloma Cells. APMIS : acta pathologica, microbiologica, et immunologica Scandinavica · 2 Sept 2026 PMID 42682210
  2. Distinct epitope engagement confers differential activity of linvoseltamab vs teclistamab across BCMA mutations. Blood advances · 27 Jul 2026 PMID 42509021
Unclassified: not yet indexed with MeSH (1)
  1. BCMA Targeted Therapies and Their Impact on Outcomes in Relapsed or Refractory Multiple Myeloma: Results From the French EMMY Cohort. European journal of haematology · 29 Sept 2026 PMID 42810732